You just read:

Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions

News provided by

Eli Lilly & Company

May 21, 2019, 13:15 ET